This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain
by Zacks Equity Research
The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.
Why Is Johnson & Johnson (JNJ) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AstraZeneca's (AZN) Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.
Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Is ALPS O'Shares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023
by Zacks Equity Research
J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
by Kinjel Shah
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Bristol Myers (BMY) Posts Data From Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.
Halozyme (HALO) Q2 Earnings and Sales Beat, Ups '22 Outlook
by Zacks Equity Research
Halozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the acquisition of Antares Pharma, the company raises its financial guidance for 2022.
Zacks Investment Ideas feature highlights: Pfizer, Caterpillar, and Johnson & Johnson
by Zacks Equity Research
Pfizer, Caterpillar, and Johnson & Johnson are part of Zacks Investment Ideas article.
3 Blue-Chip Stocks With Rock-Solid Dividends
by Derek Lewis
Blue-chip stocks are companies that have consistently provided quality, reliability, and the ability to operate profitably in the face of both good and bad times.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.
FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower loss and higher collaboration revenues in the second quarter.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.
Should WisdomTree U.S. Total Dividend ETF (DTD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DTD
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.